Kirsten R, Kirch W, Heintz B
Dtsch Med Wochenschr. 1985 Mar 8;110(10):371-6. doi: 10.1055/s-2008-1068830.
Following a placebo period of 2 weeks 39 patients with essential hypertension were given during 4 weeks a combination of 2 mg trichlormethiazide and 2 mg amiloride (Esmalorid). If the blood pressure was adequately reduced treatment was continued for a further 4 weeks; if not, a double dose was dispensed during the second 4-week period. Patients with a diastolic blood pressure under 90 mm Hg after 8 weeks when treated with a 1 mg dose, were subsequently treated with a 1 mg dose for a period of 3 months. After 8 weeks of treatment mean systolic blood pressure was reduced from 167 +/- 17 mm Hg to 151 +/- 19 mm Hg (sitting) and from 163 +/- 15 mm Hg to 148 +/- 18 mm Hg (standing), while mean diastolic blood pressure was decreased from 104 +/- 6 mm Hg to 93 +/- 8 mm Hg (sitting) and from 105 +/- 6 mm Hg to 94 +/- 8 mm Hg (standing). In 29 patients diastolic blood pressure had dropped to values under 95 mm Hg. Serum potassium remained constant during the treatment except for three patients with values outside the normal range (3.3, 3.4 and 5.2 mmol/l). The other serum electrolytes, glucose, creatinine, blood lipids, transaminases, hemogram, as well as body weight and heart rate remained unchanged. Two patients complained of side effects and did not complete the study. All other patients tolerated the treatment well.
在为期2周的安慰剂期后,39例原发性高血压患者接受了为期4周的2 mg三氯噻嗪和2 mg阿米洛利(Esmalorid)联合治疗。如果血压得到充分降低,治疗将再持续4周;如果未降低,则在第二个4周期间给予双倍剂量。在8周治疗后舒张压低于90 mmHg且服用1 mg剂量的患者,随后用1 mg剂量治疗3个月。治疗8周后,平均收缩压从坐位时的167±17 mmHg降至151±19 mmHg,站位时从163±15 mmHg降至148±18 mmHg,而平均舒张压从坐位时的104±6 mmHg降至93±8 mmHg,站位时从105±6 mmHg降至94±8 mmHg。29例患者的舒张压降至95 mmHg以下。除3例患者血清钾值超出正常范围(3.3、3.4和5.2 mmol/L)外,治疗期间血清钾保持稳定。其他血清电解质、血糖、肌酐、血脂、转氨酶、血常规以及体重和心率均未改变。2例患者抱怨有副作用,未完成研究。所有其他患者对治疗耐受性良好。